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Exome sequencing of osteosarcoma reveals
mutation signatures reminiscent of BRCA
deficiency
Michal Kovac1,2,*, Claudia Blattmann3,4,*, Sebastian Ribi1,*, Jan Smida5,6, Nikola S. Mueller7,
Florian Engert8,9,10, Francesc Castro-Giner2, Joachim Weischenfeldt11, Monika Kovacova12, Andreas Krieg13,
Dimosthenis Andreou14,w, Per-Ulf Tunn14, Hans Roland Dürr15, Hans Rechl16, Klaus-Dieter Schaser17, Ingo
Melcher18, Stefan Burdach6, Andreas Kulozik4, Katja Specht19, Karl Heinimann20, Simone Fulda8,9,10,
Stefan Bielack3, Gernot Jundt1, Ian Tomlinson2, Jan O. Korbel11, Michaela Nathrath5,6,21,** & Daniel Baumhoer1,**
Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which
has historically complicated driver gene discovery. Here we sequence exomes of 31 tumours and
decipher their evolutionary landscape by inferring clonality of the individual mutation events.
Exome findings are interpreted in the context of mutation and SNP array data from a replication
set of 92 tumours. We identify 14 genes as the main drivers, of which some were formerly
unknown in the context of osteosarcoma. None of the drivers is clearly responsible for the
majority of tumours and even TP53 mutations are frequently mapped into subclones. However,
480% of osteosarcomas exhibit a specific combination of single-base substitutions, LOH, or
large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours. Our
findings imply that multiple oncogenic pathways drive chromosomal instability during
osteosarcoma evolution and result in the acquisition of BRCA-like traits, which could be
therapeutically exploited.
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Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. 19 Institute of Pathology, Technische Universität München, Trogerstrasse 18, 81675 Munich,
Germany. 20 Medical Genetics, University Hospital Basel, Burgfelderstrasse 101, 4055 Basel, Switzerland. 21 Department of Pediatric Oncology, Klinikum Kassel,
Mönchebergstrasse 41-43, 34125 Kassel, Germany. * These authors contributed equally to this work. ** These authors jointly supervised this work. wPresent
addresses: Department of General Orthopedics and Tumour Orthopedics, Münster University Hospital, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
(D.A.). Correspondence and requests for materials should be addressed to D.B. (email: dbaumhoer@mac.com).
NATURE COMMUNICATIONS | 6:8940 | DOI: 10.1038/ncomms9940 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
O
steosarcomas (OS) are primary malignant tumours of
bone with complex karyotypes showing abundant
structural and numerical aberrations. Rapid tumour
progression and early metastatic spread are the rational for
multimodal treatment approaches that can achieve long-term
survival in about 60% of patients. Effective treatment options are
still lacking for the remaining 40% of patients suffering from
refractory or recurrent disease, however1. A partial explanation
for treatment failure might lie in different aetiologies responsible
for the structural aberrations marking the onset of the disease and
resulting in a variety of mutations in genes and pathways of
which only few are targetable. OS arise owing to mutations in the
TP53 tumour suppressor gene2–4 and a plethora of other cancer
drivers, as for example RB1 (refs 2–4), ATRX2,3, DLG23 (ref. 2),
RUNX2 (ref. 5), WRN6,7, RECQL4 (refs 5,7,8), CDKN2A/B9,
BLM7, PTEN3 and other PI3K/Akt/mTOR pathway members‘
each of which contribute only to a small proportion of patients.
As a consequence, widely applicable therapeutic targets have not
been identified so far.
The introduction of high-throughput sequencing of cancer
genomes has expanded a list of potential OS driver genes, but
disappointingly failed to provide important leads that could
improve patients’s care. In fact, data published so far only
confirmed that the intricate nature of these tumours develops
through cancer heterogeneity promoting the accumulation of
chromosomal aberrations, kataegis and chromothripsis2–4.
Marked inter- and intratumoural heterogeneity seems to be
linked to the observed differences in treatment efficacy and
clinical outcome of the respective patients10, but the particular
sets of mutations underlying these patterns, the clonal frequencies
of driver mutations and how different (sub-)populations of
tumour cells relate functionally to each other, remains largely
unknown. In this study, we search for driver gene mutations in
123 OS and attempt to reduce the complexity of their genomes by
applying abstraction analyses supplemented by clonal mapping
and ordering. Finding common traits of different cell lineages
within and between tumours seems to constitute a first step
towards developing more individualized and effective treatment
strategies in the future.
Results
Mutation processes moulding the exomes of 31 OS. Our
discovery set for whole-exome sequencing comprised 31 OS,
which were sequenced at a median depth of B150 (range
131–370) alongside with paired constitutional DNA from
peripheral blood (Table 1). All tumour samples were derived
from pre-therapeutic biopsies. Making use of Stampy and
Platypus programs for mapping and variant calling, the number
of somatic base substitutions (single-nucleotide variants (SNVs))
and indels called with high confidence ranged from 7 to 3,153
(median¼ 66.5) and 17 to 529 (median¼ 33.5) per exome,
respectively. Of these, a median of 21 SNV changes (range 4–174)
and seven small indels (range 2–210) were potentially functional
within protein-coding regions. The SNV spectrum for each OS
exome is shown in Fig. 1a and Supplementary Figs 1 and 2. With
two exceptions, the C:G4T:A changes were the most common
changes followed by C:G4A:T and T:A4C:G changes. The
mutation burden of OS was similar to the ageing signature of
most tumour types from the pan-cancer analysis11, however,
a decomposition of mutation spectra with a non-negative
matrix factorization algorithm revealed a pattern similar to the
signatures 3 and 5 (Fig. 1b and Supplementary Fig. 3). A subset of
tumours of this class is known to acquire a characteristic pattern
of substitution mutations including kataegis and the presence of
signature 3 was strongly associated with BRCA1 and BRCA2
mutations within breast and pancreatic cancer types11,12.
Driver mutations impair cell control of genome integrity. For
the discovery of somatic driver mutations we restricted our
analysis to protein-coding regions. A minimum variant allele
frequency of 0.05 was set. We then prioritized genes for further
investigation by filtering mutations to exclude all SNVs with
moderate or benign predicted functional effects (Sorting
Intolerant From Tolerant (SIFT) score¼o0.05 and Mutation
Taster and PolyPhen2 40.8). All protein-truncating and splice-
site mutations were retained. We then identified genes that were
mutated in two or more tumours and inspected all variant reads
in the Integrated Genome Viewer to exclude any mutations
at sites of evidently poor quality. Eventually, 26 genes
(Supplementary Data 1) including some that had already been
reported in the context of OS (for example, ARTX, SFPQ,
FGFRL1 and RB1) remained2–4,13.
Since patients with Werner, Li–Fraumeni, Rothmund–
Thomson and Bloom syndromes have a comparably higher risk
of OS8,14,15, we examined our sequencing data for germline
mutations in the WRN, TP53, RECQL4 and BLM genes. We
identified two germline TP53 mutations (OS-241 and OS-228),
one germline WRN mutation in addition to loss of heterozygosity
(LOH) around the locus (OS-230) and two rare germline
RECQL4 variants with unknown significance (OS-227 and OS-
238). We then applied the same prioritization scheme to the
remainder of genes with germline variants. Prioritized cancer
drivers not previously reported in OS included RET, MUTYH,
NUMA1, FANCA, BRCA2 and ATM. We chose these genes for
further investigation, based on the presence of at least two clearly
pathogenic mutations and/or co-segregation of mutations with
cancer in the respective families. Furthermore, these genes were
excellent functional candidates.
We validated mutations detected in 388 genes (Supplementary
Data 2) by Ion Torrent sequencing in the discovery set of
tumours and then undertook replication testing of 30 genes
(Supplementary Data 3) in a set of additional 92 unpaired
OS. The analysis of merged variant calls from 123 tumours
yielded a total of 22, 10 and 11 TP53, RB1 and ATRX
mutations, respectively (Supplementary Table 1). Three tumours
acquired somatic RET mutations. One patient, OS-250, carried a
germline RET mutation, which at the time of diagnosis
had not yet manifested by multiple endocrine neoplasia type 2
but the mutation co-segregated with breast cancer and
rhabdomyosarcoma in two first-degree relatives. Two de novo
germline RET mutations previously associated with late-onset
multiple endocrine neoplasia type 2 were identified in
patients OS-224 and OS-242. We also identified seven MUTYH
mutations (germline or somatic) and four, four, three and
one mutations in the FANCA, MDC1, NUMA1 and PTEN
genes, respectively. Somatic missense mutations in MDC1 and
NUMA1 genes affected conserved residues of protein domains
encoding nuclear localization signal and/or interacting with
other proteins of BRCA complex, for example CHEK2.
MUTYH mutations were equally distributed between an endo-
nuclease domain and a NUDIX-type hydrolase domain. There
were also two somatic WRN mutations affecting a
DNA-binding domain and three germline mutations in the
ATM gene, two of which have been linked to breast cancer
susceptibility before16,17.
The Intogen18 pathway analysis reassuringly identified ATRX
and RB1 as the main drivers (Supplementary Data 4). The
Intogen list of drivers did not include TP53 since there was only
one mutation in the discovery set of tumours, but TP53 and three
other genes (RB1, ATRX and ATM) were notably reported by
Intogen as drivers in the pan-cancer analysis19. Exploring gene
ontology of the remaining genes we found that many, if not all
genes, have been functionally related to DNA damage repair,
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chromosomal segregation and cell cycle control of genome
integrity8,20–24.
Structural and copy-number alterations. We next turned our
attention to somatic copy-number alterations (SCNA; Fig. 2a,b),
which affected 0.2 (OS-251) to 87% (OS-038) of OS genomes.
The median size of a SCNA called with high-sensitivity
settings was 4.7 Mb and a typical genome contained 69 of such
events. Analysis of single-nucleotide polymorphism arrays using
dedicated data-processing methods identified large-scale genomic
instability25 and LOH26,27 signatures similar to that of breast and
ovarian cancers with BRCA1/2 inactivation in 91% (112/123;
Fig. 2c) and 78% (96/123; Fig. 2d) of OS, respectively.
The most frequent SCNA events involved gains of the long arm
of chromosome 8 (75%). It has been plausibly suggested that
gains of 8q target MYC in OS, but chromosome 8 gains in our set
of tumours involved very long segments without evidence of
targeting any gene specifically. Similarly, other frequent gains of
1p (55%), 1q (53%), 5p (46%), 6p (56%), 17p (66%) and 18p
(33%) involved large regions. Large deletions were almost as
Table 1 | Clinicopathological and summary mutation data for each OS.
ID Age Histology Site SNV Indels Dn:Ds Ts:Tv %SCNA Clonality
OS-046 10 Mixed Femur 91 24 2.8 1.76 67.45 3
OS-059 13 Osteoblastic Fibula 50 29 1.18 1.38 67.1 4
OS-061 12 Chondroblastic Femur 106 36 1.8 1.65 67.5 7
OS-063 17 Teleangiectatic Humerus 127 48 1.13 1.75 64.3 6
OS-065 15 Osteoblastic Tibia 78 34 1.75 1.43 44.2 3
OS-079 45 Osteoblastic Femur 48 20 2.35 1.17 56.2 2
OS-224 11 Osteoblastic Tibia 310 397 1.62 1.64 57.1 14
OS-225 14 Osteoblastic Tibia 38 25 1 1.53 50.8 2
OS-226 11 Osteoblastic Tibia 52 36 1.77 1.36 57.8 6
OS-227 19 Osteoblastic Femur 29 32 3 1.41 0.2 3
OS-228 13 Chondroblastic Femur 48 24 2 1.28 59.3 4
OS-230 18 Chondroblastic Tibia 192 185 1.5 1.23 62.5 11
OS-231 13 Chondroblastic Tibia 195 246 1.39 1.18 81.8 8
OS-232 21 Extraosseous Femur 606 529 2.59 1.18 61.1 16
OS-234 17 Osteoblastic Humerus 46 20 3.8 1.29 60.5 4
OS-235 14 Osteoblastic Tibia 52 23 1.7 0.79 76.2 5
OS-236 19 Chondroblastic Femur 46 37 2.6 1.29 59.4 5
OS-237 14 Chondroblastic Femur 29 28 1.33 1.89 44.9 5
OS-238 17 Osteoblastic Tibia 63 33 2 2.49 38.3 6
OS-240 15 Osteoblastic Femur 32 19 3.75 1.66 15.6 6
OS-241 5 Osteoblastic Fibula 7 19 – 0.4 NA 2
OS-242 14 Osteoblastic Tibia 35 17 7.33 0.94 26.4 4
OS-250 14 Osteoblastic Femur 70 35 1.25 0.79 20.5 4
OS-251 9 Osteoblastic Femur 106 38 1.64 0.89 0.2 9
OS-252 16 Chondroblastic Femur 253 33 0.82 2.37 34.7 4
OS-253 6 Chondroblastic Tibia 71 47 3.33 0.82 56.7 3
OS-253M 6 Chondroblastic Lung 167 56 2.15 0.77 70.1 12
OS-254 27 Mixed Fibula 33 20 1.25 2.14 30.1 1
OS-255 12 Chondroblastic Tibia 3,153 459 2.56 2.01 33.9 7
OS-256 17 Osteoblastic Tibia 50 44 2 1.78 55.6 4
OS-257 12 Mixed Tibia 1,993 345 1.35 1.92 17.6 4
OS-258 20 Unknown Humerus 104 29 2.22 1.66 29.4 7
NA, not applicable
SNV denotes high-quality somatic single-nucleotide variants; Dn:Ds denotes the ratio of non-synonymous to synonymous exonic mutations; Ts:Tv denotes a ratio of somatic exonic transitions to
transversions; % genome changed by SCNA, per cent of genome affected by copy-number changes; clonality denotes a number of clones estimated by PyClone algorithm.
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Figure 1 | Somatic SNV spectra and mutation signatures. (a,b) Data are derived from exomes of each tumour. Note that OS with very few somatic
SNVs are included for sake of completeness.
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common as gains, the most frequent involving chromosomes
3 (50%), 6q (45%), 5q (40%), 8p (43%), 10 (56%), 13 (50%),
16 (64%), 17 (47%), 18q (34%) and 19 (54%). Deletions of
these chromosomes almost invariably included main OS drivers
including TP53, BRCA2, RET, WRN, FANCA and RB1 (Fisher
exact test, Po0.01; Supplementary Fig. 4). We also found good
evidence supporting SCNA mutations in the BRCA1 gene itself
(26%) and in members of the homologous recombination repair
pathway—BAP1 (38%), PTEN (50%) and PALB2 (43%)—in
which exome sequencing did not identify any mutation.
We specifically searched for small (o1 Mb) and focal
SNCAs that might represent oncogene amplifications or tumour
suppressor deletions. After filtering out common variants,
20,758 regions were identified although only 80 were
found to be recurrent (defined as having frequencies 415%;
Supplementary Fig. 5 and Supplementary Data 5). Two focal
SCNA involved gene loci with a strong a priori importance
in OS2,9, including a deletion of CDKN2A/2B located at
chromosome 9p21 (15%) and a deletion of DLG2 at
chromosome 11q14 (24%). Other SCNA were detected in
known fragile sites (WWOX, for example), deeply intragenic
regions as well as microRNAs and genes with no prior association
to cancer.
We then assessed the significance of called SCNA regions by
using a random sampling model similar to the GISTIC analysis
(Supplementary Figs 6 and 7). After filtering for SCNAs with
adjusted P values o0.01, 92, 412 and 322 amplifications (copy
number 44), gains (copy number¼ 3) and deletions (copy
number o2) remained (Supplementary Data 6), respectively.
TP53, RB1, PTEN, RUNX2, BAP1 and CDKN2A/B genes were
reassuringly among the over-represented SCNA regions, as well
as several new loci including a homozygous loss of interferon
genes on chromosome 9 (chr9: 21,248,029–21,408,261) and an
amplification of a 10-gene locus on chromosome 1 (chr1:
59,762,489–62,907,413). We then re-examined each candidate
SCNA events for association with overall and/or disease-free
survival using the Cox regression model. Five loci (including
CDKN2A/B and TP53) were associated with an adverse outcome
of patients (Supplementary Fig. 8). Three SCNA loci were
associated with earlier onset of disease (Supplementary Fig. 9).
BRCAness as an emergent property of OS. Our hypothesis of
‘BRCAness’ does not replace the existing view of OS as a
monoclonal expansion of one initial TP53 mutant cell, but rather
offers an explanation of how the vulnerability to chromosomal
breakage may be sustained parallel to or in the absence of TP53
mutations. Using PyClone28 estimates of cellular frequencies we
found that TP53 and RB1 driver mutations were clonal events in
58 tumours (47%; Fig. 3). The remaining tumours (n¼ 65, 53%)
showed good evidence of the acquisition of genomic
instability through alternative pathways—for example, by
MUTYH mutations20—well before TP53, RB1 mutations and/or
BRCA-like traits emerged. We envision that OS at this stage also
acquired a propensity to shatter into subpopulations of cancer
cells. Given enough time, different cancer cell lineages are likely
to acquire private SCNAs in the BRCA1/2 genes (and in their
67 binding partners) simply by chance, and by the time the
disease emerges, different clonal populations will have already
gained partial or full deficiency in homologous recombination
repair. We find this view consistent with evidence that, on
average, a typical OS carries 17 SCNA mutations in BRCA genes
and their core binding partners (Fig. 4a and Supplementary
Data 7), mutations in different ‘BRCA’ genes can be functionally
equivalent (for example, PALB2, CHEK2, PTEN and ATM
mutations result in chromosomal instability analogous to
BRCA1/2 mutations29–33) and OS are polyclonal (Table 1).
We therefore estimated the relative importance of each of the
69 ‘BRCA’ genes from the clonality of their SCNA mutations. For
Fig. 4b we used a clustering method based on Euclidian distances;
the individual position of each gene in the plot is the product of
clonal and subclonal frequencies of its SCNA events. It is not
surprising that the most frequently mutated and thus outlying
genes were TP53, RB1, BRCA2 and PTEN, and that TP53 and RB1
became even more outlying when SNV changes were included.
In fact, TP53 and RB1 were the only two genes mutated with
somatic SNV/indel mutations at a frequency 43%. Putative
cancer drivers with a propensity to carry clonal SCNAs were an
android receptor gene, the RNA gene XIST, the BRCA1 binding
partners RBBP7 and NCOA2, a BRCC3 metaloprotease unit of the
BRISC complex and CSTF2 that prevents inappropriate RNA
processing at sites of DNA repair.
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Efficacy of talazoparib inhibition in OS cell lines. Currently
there is no available OS cell line, which is fully deficient in BRCA1
or BRCA2. Although this may constitute a bottleneck for current
experimental approaches, some OS cell lines can carry mutations
in other genes of the homologous recombination pathway leading
to defects functionally analogous to BRCA1 and BRCA2 muta-
tions (Fig. 4c). We tested three cell lines, one being a double
mutant in PTEN and ATM (MNNG/HOS) and two with
heterozygous SCNA mutations in the checkpoint kinase 2 CHEK2
(SAOS2) and FANCD2 gene (SJSA-1), respectively. SJSA-1 and
SAOS2 cells were included in the study mainly for comparative
purposes since the heterozygous mutations did not seem
sufficient to result in homologous recombination repair
deficiency. Indeed, in vitro tests showed only a limited response of
SAOS2 and SJSA cells to a standalone 72-h treatment with
the phase-3 poly ADP ribose polymerase (PARP) inhibitor
talazoparib (Fig. 5). By contrast, MNNG/HOS cells showed good
evidence of IC50 after standalone treatment, and even a better
response when talazoparib was combined with the alkylating
agent temozolomide and the topoisomerase I inhibitor SN-38.
The reason for pursuing combined treatment strategies was that
the cytotoxicity of talazoparib results from the availability of
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Figure 4 | Copy-number alterations in BRCA1/2 and binding partners. (a,b) Frequencies of clonal and subclonal SCNA mutations. (c) SCNA
mutational profiles of selected OS cell lines.
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single-stranded DNA breaks, which temozolomide and SN-38 are
particularly effective in creating34. Talazoparib concentrations of
up to 5 mM used in our experiments have been considered
therapeutically achievable concentrations in vivo according to a
recent study of Hopkins et al.35.
Discussion
Cataloguing mutations from 123 tumours has yielded several new
insights into the underlying mutational mechanisms in OS.
We identified clearly monoclonal mutation events in TP53 or RB1
in 47% of cases, whereas additional 40% of tumours could be
explained by invoking mutations in alternative driver genes.
Eight of these genes—BRCA2, BAP1, RET, MUTYH, ATM,
PTEN, WRN and RECQL4—are well-known Mendelian cancer
drivers, whilst the four remaining genes (ATRX, FANCA,
NUMA1 and MDC1) have been reported in the context of cancer
susceptibility2,22–24. In total, 87% of OS could be explained by any
of the 14 driver genes. Our findings thus supplement the
‘traditional’ TP53-centred model of OS evolution such that
molecular pathways functionally similar to TP53 can drive its
initial phases by conferring to genome instability. Tumours
without clonal TP53 mutations may still acquire subclonal TP53
mutations later which adds B25% to the total mutation
prevalence. This is important to realize when interpreting
findings of other studies as, for example, Chen et al.2 reported
structural and SNV mutations in TP53 in 30 of 34 genome-
sequenced tumours. In a second study, whole-exome sequencing
of 53 paediatric OS yielded a 75% prevalence of TP53 mutations3.
The difference between these and our estimate might in part
result from our inability to identify rearrangements within the
first intron of TP53 (which we estimated at 15% frequency36), but
other aspects being equal, we conclude that not all previously
reported TP53 mutations are clonal and thus represent the
triggering event. Instead we envision a situation, in which
multiple oncogenic pathways drive chromosomal aneuploidy and
instability in early stages of OS evolution.
Mutational landscapes of two tumours without TP53 muta-
tions (Fig. 6) shall illustrate our hypothesis. The first tumour
(OS-046) does likely acquired a homozygous mutation in
NUMA1, resulting in mitotic segregation errors that at some
point led to the chromoplexy of chromosomes 2, 8 and 17 driven
by inter-chromosomal exchanges. The evidence supporting
NUMA1 mutation as a triggering event in OS-046 stems
from the fact that all somatic SNV mutations were monoclonal,
which would be hardly possible if they were sequential to the
chromosomal instability. Similarly, an early evolutionary history
of the second tumour (OS-059) could have been driven either by
a germline MUTYH mutation or by a somatic RB1 mutation.
Mutations in both genes were found hemizygous in a tumour,
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Figure 5 | Cell viability assays. MNNG, SAOS2 and SJSA-1 OS cells were treated for 72 h with indicated talazoparib, temozolomide and SN-38
concentrations. Cell viability was assessed by a MTT assay and is expressed as percentage of untreated cells. Data are shown as mean±s.d. of three
independent experiments, each performed in triplicates. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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both mutations were clonal events and the functions of both
genes are related to chromosomal instability2,20. However, a
parsimonious explanation would still favour a single somatic hit
in the MUTYH gene over two somatic hits in RB1.
In a recent study Nik-Zainal et al.12 described a distinct profile
(which they termed profile D) of substitutions and deletions in
breast cancer with BRCA1/2 mutations, which later was reported
by Alexandrov et al.11 as signature 3 in a pan-cancer analysis.
With two outliers (OS-241 and OS-079) we found this signature
(as a combination of signatures B and C; Fig. 1b) in 29/31 (94%)
tumours from which exome-sequencing data were available. This
seems particularly interesting because early evolution of OS has
historically been attributed to TP53 and RB1 driver mutations,
but the root molecular cause of its genomic complexity (in later
phases) remains unclear. Seeking to validate this finding we
turned to whole-genome copy-number profiles of 123 OS and
specifically looked for characteristic large-scale copy-number
changes that also constitute the hallmark of BRCA1/2-mutated
breast cancer12. Surprisingly, 84% of the analysed tumours
fulfilled these criteria, suggesting that exome findings are likely to
be correct and that various degrees of BRCAness are acquired
throughout OS evolution. A recent study in ovarian cancer
developed a LOH-based homologous recombination deficiency
score, which reflects the number of subchromosomal LOH
segments with a size exceeding 15 Mbp. Intriguingly, a high
homologous recombination deficiency-LOH score, as seen in 78%
of OS assayed in our study, was shown to correlate with
deficiency in homologous repair and a positive response to a
combination treatment including a PARP inhibitor in breast
cancer27.
Putative deficiency in homologous repair and other similarities
between OS and tumours with BRCA-like phenotype indicate
a specific weakness that could be therapeutically exploited.
Specifically, the inhibition of PARPs contributing to DNA
damage repair was shown to induce cell cycle arrest and
apoptosis in BRCA1-, BRCA2- and PALB2-deficient breast
cancers29,37. Furthermore, cancer cells with mutations in the
ATM pathway members and PTEN gene were also shown to be
sensitive to PARP inhibitors, thus raising the possibility that a
‘synthetic lethality’ approach could also be effective in OS30,33.
We sought to test this possibility on selected OS cell lines
(MNNG/HOS, SAOS2, SJSA-1, ZK58, HOS, MG-63 and U2-OS)
but none of them carried bi-allelic BRCA1/2 mutations. We
found, however, a good response of MNNG/HOS cells carrying a
disruptive gain in the PTEN gene and a deletion of the ATM gene
to a standalone treatment with the phase-3 PARP inhibitor
1
2
3
4
5
6
7
8
910
11
12
13
14
15
16
17
18
19
20
21
22
x
y
M
U
T
Y
H
N
U
M
A
1
FANCA
RUNX1
BA
RD
1
C
H
EK2
BRCA1
BR
CA
2
PA
R
P
1
RAD51
PALB2
MDC1
P
T
E
N
BA
P1
TP53
AT
M M
Y
C
R
E
T
RB
1
1
2
3
4
5
6
7
8
910
11
12
13
14
15
16
17
18
19
20
21
22
x
y
M
U
T
Y
H
N
U
M
A
1
FANCA
RUNX1
BA
RD
1
C
H
EK2
BRCA1
BR
CA
2
PA
R
P
1
RAD51
PALB2
E
P
300
MDC1
P
T
E
N
BA
P1
TP53
AT
M M
Y
C
R
E
T
RB
1
Chr8
a b
Chr1
c
Chr17
Subclonal SCNAs
Chr17
0.4 0.6 0.80.20 1.0
NUMA1
C7
GPR55
EPS8L2
ZSCAN26
TNXB
DSP
OR6C70
TOPAZ1
MBD2
RAPGEF2
SHMT2
C12orf42
RGAG1
OR10H1
C6orf201
TMPRSS15
RPTN
ETF1
TP53BP1
CXXC4
GGN
0.4 0.6 0.80.20 1.0
RB1
MUTYH
WRN
MDC1
SOAT2
OR51F1
TNIP3
CCDC123
VWF
FOXJ3
PDK3
TDRD7
RP1L1
CBX4
TBC1D4
WNK2
ERI3
TNRC6A
SESTD1
DEPDC5
TLR6
FAM194B
GXYLT2B
FAM118A
Cellular frequencyOS-046
OS-059
Cellular frequency
–2 20
Chr1
Ga
ins
Lo
ss
es
0 Mb
50 Mb
100 Mb
150 Mb
200 Mb
MUTYH
–2 20
Chr17
0 Mb
20 Mb
40 Mb
60 Mb
80 Mb
Ga
ins
Lo
ss
es
TP53
BRCA1
–2 20
0 Mb
Chr10
25 Mb
50 Mb
75 Mb
100 Mb
125 Mb
Ga
ins
Lo
ss
es
PTEN
RET
Chr2
Chr10
Subclonal SCNAs
–2 20
Chr8 Chr17
–2 20
0 Mb
20 Mb
40 Mb
60 Mb
80 Mb
TP53
BRCA1
MYC
Ga
ins
Lo
ss
es
Ga
ins
Lo
ss
es
Ga
ins
Lo
ss
es
–2 20
Chr2
50 Mb
100 Mb
150 Mb
200 Mb
BARD1
0 Mb
25 Mb
50 Mb
75 Mb
100 Mb
125 Mb
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talazoparib. Combined with the alkylating agent temozolomide or
the topoisomerase I inhibitor SN-38, 0.1 and 5mM concentrations
of talazoparib led to an even greater decrease of MNNG/HOS cell
viability, respectively. Furthermore, a good response of HOS and
MG-63 cells to the phase-2 PARP inhibitor olaparip was recently
reported by Smith et al.29.
Using OS cell line experiments impose a few limitations to our
study, however. Perhaps the most striking one stems from the
paucity of OS cell lines truly deficient in BRCA1/2. This may
be surprising, but it should be noted that OS cell lines arise
through monoclonal expansions of one cancer cell surviving
immortalization, which may not necessarily be the most common
cell type in the tumour it is derived from. The molecular portrait
of OS presented here prerequisites the existence of intratumour
heterogeneity, which is in fact lost in vitro. The polyclonal nature
of OS also implies that BRCA-like traits of OS genomes might
result not only from BRCA1/2 mutations alone but also from
mutations in other genes of the homologous recombination
pathway, each of which confers to additional biological
properties. These limitations do not invalidate our findings or
conclusions, but suggest that, for example, responsiveness of
individual tumours to PARP inhibitors will not only depend on
the proportion of cancer cells with BRCA-like features but also on
the specific mutations and genes that bring about homologous
recombination deficiency.
In conclusion, the presented data support a BRCA-like
phenotype as a unifying trait of OS independently of which
oncogenic pathway drives tumorigenesis. We have shown that at
least 14 different genes underlie the disease, including Mendelian
cancer drivers for which OS has not been reported to belong
within their phenotypic repertoire. More importantly, the effect
of mutations within different genes and pathways seem to
complement each other and result in a specific signature
characteristic for BRCA1/2-deficient tumours. Our findings
warrant further testing of PARP inhibitors in experimental
settings and eventually sequencing of individual tumours for
therapeutically targetable driver gene mutations.
Methods
Sample description. The discovery set comprised 31 previously untreated OS
samples, paired with peripheral blood or normal tissue. A paired primary tumour
and a metastasis was sequenced in one patient. Informed consent was obtained from
all patients and ethical approval was obtained from the local ethical
committee of Heidelberg (project no. S-327/2011) for the analysis of anonymized
samples and for the purpose of driver gene discovery. All tumour samples were
re-evaluated by an experienced bone pathologist and confirmed the diagnosis and a
tumour content 470% per sample. Genomic DNA was extracted from each tumour
and paired blood sample using standard methods. The replication set comprised 92
unpaired frozen pre-therapeutic tumour biopsies, which were subjected to the DNA
extraction the same way as the 31 tumours of the discovery set.
Exome sequencing. Exome capture was performed using the Agilent SureSelect
kits (version 4). Samples were quantified using the Qubit system (Invitrogen) and
sequencing libraries constructed from 1 mg DNA. Samples were sequenced using
the Illumina HiSeq 2000 platform as paired 100-bp reads with Chemistry version
3.0, with the aim of target coverage of 100 for the blood DNA and 200 for the
tumours. After removal of PCR duplicates using Picard, reads were mapped with
Stampy version 1.0.12 onto the Human Reference Genome (GRCh37d5/hg19).
SNVs and small indels were called with Platypus version 0.5 using the tumour-
normal pairs of bam files together to ensure comparable calls at every locus.
Variants were only called if they were assigned sufficiently high posterior
probability (phred score 420). We removed the allele bias filter to increase
sensitivity. Finally, for selected variants, we made sure that the automatic call
matched the data by expert visual inspection of the mapped reads onto the
reference genome using read direction colouring on top of the standard integrated
genomic viewer scheme.
Annotation was performed using ANNOVAR using hg19 reference genome
and 2014 versions of standard databases and functional prediction programs.
We excluded duplicated genomic regions (490% homology) from the analysis and
variants within regions with low mapability scores. Variants were annotated with
ANNOVAR Refseq gene model using dbSNP(135); 1,000 genomes project allele
frequencies (October 2014), 6,500 exome-sequencing project allele frequencies,
University of Santa Cruiz (UCSC) segmental duplication scores and UCSC 46
species conservation scores and predictions of functional importance from SIFT,
PolyPhen2 and Mutation Taster.
For filtering of variant calls for analysis, calls were first compared between
matched constitutional and tumour samples to identify somatic mutations. For the
analysis of mutation burden and mutation spectra, we applied the following
exclusion filters to somatic variants: (i) presence in a segmental duplication region
or a region with mapability score o0.5; (ii) variant present in any read from paired
normal sample; (iii) fewer than 10 reads in total at the variant site in the normal
sample; (iv) fewer than 8 reads in total in the tumour; (v) fewer 3 three variants in
the tumour; variant allele frequency o5% in the tumour; and (vi) presence of
variant in public databases (Exome Variant Server, 1,000 genomes project and
Complete Genomics 69 reference genomes) at a frequency 42%. Variants
identified in constitutional DNA from any of the other local, non-cancer
sequencing project (for example, 29 million variants across 284 samples from the
Oxford-Illumina WGS500 consortium) were discarded as being more likely due to
systematic error in our pipeline than genuine somatic mutations.
Ion Torrent technical replication. Technical replication of mutations identified by
exome sequencing of 31 OS was carried out by Ion Torrent sequencing using a
custom Ion AmpliSeq 388 gene panel (gene list and genomic coordinates available
as Supplementary Data 2). Approximately 100 ng DNA was used for sequencing.
We sequenced to an average depth of 300 and used the Ion Reporter software for
variant calling. Variant calls were annotated using the ANNOVAR software and
the same databases as for exome-sequencing data. Variants present in the exomes
were assessed alongside the equivalent Ion Torrent data. In addition, visual
inspection with the integrated genomic viewer genome browser was required for
variant calls with posterior quality scores of 20–30. For specific RET mutations we
tested additional family members by Sanger sequencing. In addition, we used the
Ion AmpliSeq 388 gene panel to validate mutations from 15 randomly picked
samples that underwent Illumina MiSeq sequencing.
Targeted Illumina re-sequencing. Biological replication was carried out using
1 mg of DNA from 92 additional tumours and Illumina MiSeq re-sequencing to an
average depth of 480 . The custom Nimblegen target enrichment kit was used to
capture all exons of 30 genes (that is, 13 main OS drivers and their 17 interaction
partners; Supplementary Data 2) and a B20-kb region encompassing the TP53
gene. An average coverage of the target region was 92%. Read mapping, filtering
and variant calling was done with the Stampy-Platypus pipeline using the same
setting as for the discovery set of 31 exomes.
Mutation spectra and signatures. For each tumour, somatic SNV frequencies
were calculated and the deviation of their spectra from the background
(determined across all samples) was assessed using w2-test (df¼ 5). The
trinucleotide spectrum was normalized according to 3-mer frequencies in the
reference exome (Agilent SureSelect (version 4)). Somatic mutation signatures were
inferred using the R package38, in which a mutation spectrum was decomposed
with a non-negative matrix factorization algorithm. The decomposition was
performed for prior sets of 2, 3 and 4. The optimal number of signatures (r¼ 3)
was manually chosen based on the maximum differentiation between the
signatures. The signature analysis was repeated 10 times with the same results
obtained after each run.
Affymetrix CytoscanHD array data analysis. Affymetrix CytoscanHD arrays
were processed with ChaS 2.1 and Nexus 7.5 software such that SCNA events larger
than 50 kb with a minimum support of 21 probes were considered for subsequent
analysis. Gene annotations were extracted using Ensembl REST API GRCh37
assembly. We assessed statistical significance of called SCNA regions by an
algorithm similar to the GISTIC39 analysis, which identifies SCNA with frequency
higher than expected by chance. Concretely, for each chromosome SCNA events
were resampled to generate uniform distribution and then significance was assessed
across all positions in 1-kb windows by deriving Benjamini–Hochberg adjusted
P values (q values). Each candidate SCNA was subjected to survival analysis with
subsequent multiple testing correction using Benjamini–Hochberg q values o0.05.
For event-free survival and overall survival we used Cox proportional hazards
regression model.
In vitro cell line experiments. OS cell lines were grown in RPMI 1640 medium
(SJSA-1), minimum essential medium supplemented with 10% fetal calf serum
(MNNG/HOS) or in McCoy’s 5A medium supplemented with 15% fetal calf
serum. Talazoparib was obtained from Selleckchem (Munich, Germany). Control
tests for mycoplasm contamination were carried out routinely (two times a month)
using a PCR-based and commercially available detection kit according to the
manufacturer’s protocol (VenorGem, Minerva Biolabs, Berlin, Germany).
Furthermore, authentication of cell lines has been carried out by genotyping using
microsatellite markers (Supplementary Data 8) to exclude cross-contaminations.
Cell viability was assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide assay according to the manufacturer’s instructions
(Roche Diagnostics, Mannheim, Germany). Statistical significance was assessed
by Student’s t-test (two-tailed distribution, two sample, unequal variance).
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